Finder makes money from featured partners, but editorial opinions are our own.

Oncology stocks

Ready to invest in the cancer industry? Consider these 9 stocks.

The best oncology stocks depend on your portfolio and investment goals — while volatility can be ideal for day traders, long-term investors will want to look to stocks with steadier gains over time.

Best for Beginners

CIBC Investor's Edge

  • Easy to use platform
  • Low fees
  • Student and young investor discounts

Best for Lowest Commissions

Finder Award

Interactive Brokers

  • Access to international stock exchanges
  • Low margin rates
  • Powerful research tools

Best for Easy-to-use App


  • $50 in free trades
  • Low commissions
  • Easy-to-use app

Our picks for the best oncology stocks

We round up a selection of stocks in or related to the cancer industry, weighting the list more heavily towards popular mid- and large-cap US stocks.

1. Amgen (AMGN)

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas.

  • Previous close price: $271.46
  • Market capitalization: $139,459,379,200
  • 1 year performance: 17.44%
  • P/E ratio: 17.5569
Buy AMGN stock on Interactive Brokers

2. Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

  • Previous close price: $58.78
  • Market capitalization: $122,483,933,184
  • 1 year performance: -17.81%
  • P/E ratio: 15.5931
Buy BMY stock on Interactive Brokers

3. Five Prime Therapeutics (FPRX)

Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on the development of immuno-oncology and targeted cancer therapies. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b to treat patients with gastric or gastroesophageal junction and GEJ cancer; FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28 that is in Phase Ia/1b clinical trial for patients with solid tumors; and BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase I/II clinical trial in combination with Opdivo in patients with advanced malignant tumors.

  • Previous close price: $0.00
  • Market capitalization: $1,769,735,936
  • 1 year performance: N/A
Buy FPRX stock on Interactive Brokers

4. Gilead Sciences (GILD)

Gilead Sciences, Inc. , a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.

  • Previous close price: $75.82
  • Market capitalization: $96,391,331,840
  • 1 year performance: 11.48%
  • P/E ratio: 17.7839
Buy GILD stock on Interactive Brokers

5. Novartis AG ADR (NVS)

Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians.

  • Previous close price: $103.58
  • Market capitalization: $210,610,913,280
  • 1 year performance: 23.90%
  • P/E ratio: 28.2861
Buy NVS stock on Interactive Brokers

6. Cardiff Oncology (CRDF)

Cardiff Oncology, Inc. , a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and hematologic malignancies, such as KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.

  • Previous close price: $7.66
  • Market capitalization: $82,652,824
  • 1 year performance: -49.22%
Buy CRDF stock on Interactive Brokers

7. Surface Oncology (SURF)

Surface Oncology, Inc. , a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8.

  • Previous close price: $7.12
  • Market capitalization: $65,690,464
  • 1 year performance: -23.57%
Buy SURF stock on Interactive Brokers

8. Trillium Therapeutics (TRIL)

As of November 17, 2021, Trillium Therapeutics Inc. was acquired by Pfizer Inc. Trillium Therapeutics Inc.

  • Previous close price: $8.63
  • Market capitalization: $1,936,107,904
  • 1 year performance: N/A
Buy TRIL stock on Interactive Brokers

9. Mersana Therapeutics (MRSN)

Mersana Therapeutics, Inc. , a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC.

  • Previous close price: $1.27
  • Market capitalization: $162,684,448
  • 1 year performance: -84.11%
Buy MRSN stock on Interactive Brokers

How to buy oncology stocks

With an online trading account, you can buy oncology stocks in a few simple steps:
  1. Compare online trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Use our comparison table to narrow down top brokers by fees and bonuses.
  2. Open and fund your account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for the stock you're interested in. Find the stock by name or ticker symbol, like AMGN or BMY. Research its history to confirm it's a solid investment against your financial goals.
  4. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy fractional shares, depending on your broker.
  5. Buy the stock. Congratulations, you own a part of an oncology company. Optimize your portfolio by tracking how your stock — and even the sector as a whole — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Buy oncology stocks from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 4 of 4
Name Product Finder Rating Available Asset Types Stock Trading Fee Account Fee Signup Offer Table description
Interactive Brokers
Finder Rating:
4.3 / 5
Stocks, Bonds, Options, ETFs, Currencies, Futures
min $1.00, max 0.5%
Winner for Best Overall Broker in the Finder Stock Trading Platform Awards.
CIBC Investor's Edge
Finder Rating:
3.8 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs
$0 if conditions met, or $100
An easy-to-use platform with access to a variety of tools to help you trade with confidence.
Finder Rating:
4.3 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95 - $9.95
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio to take out some of the guesswork.
Qtrade Direct Investing
Finder Rating:
3.7 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Get up to $150 cashback. Use promo code OFFER150. Conditions apply. Ends October 31, 2023.
Low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options.

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

Bottom line

While it's possible to turn a profit investing in oncology stocks, keep in mind that — like any investment — oncology stocks are not immune to risk. These stocks are subject to fluctuating conditions — both in the market and in the cancer industry, so carefully vet your picks before you invest. And if you're new to investing, or if it's been awhile since you've taken a critical look at your investing accounts, compare brokers to make sure you're getting the best features in your trading account.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site